Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance

被引：163

作者：

Park, Young-Jun ^{[1
,2
]}

Kuen, Da-Sol ^{[1
,2
]}

Chung, Yeonseok ^{[1
,2
]}

机构：

[1] Seoul Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Lab Immune Regulat, Seoul 08826, South Korea

[2] Seoul Natl Univ, Coll Pharm, Plus Program BK21, Seoul 08826, South Korea

来源：

EXPERIMENTAL AND MOLECULAR MEDICINE | 2018年 / 50卷

基金：

新加坡国家研究基金会;

关键词：

T-CELL EXHAUSTION; LONG-TERM SAFETY; PD-1; BLOCKADE; METASTATIC MELANOMA; CTLA-4; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; UP-REGULATION; ANTIBODY; IPILIMUMAB;

D O I：

10.1038/s12276-018-0130-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent advances in the understating of tumor immunology suggest that cancer immunotherapy is an effective treatment against various types of cancer. In particular, the remarkable successes of immune checkpoint-blocking antibodies in clinical settings have encouraged researchers to focus on developing other various immunologic strategies to combat cancer. However, such immunotherapies still face difficulties in controlling malignancy in many patients due to the heterogeneity of both tumors and individual patients. Here, we discuss how tumor-intrinsic cues, tumor environmental metabolites, and host-derived immune cells might impact the efficacy and resistance often seen during immune checkpoint blockade treatment. Furthermore, we introduce biomarkers identified from human and mouse models that predict clinical benefits for immune checkpoint blockers in cancer.

引用

页码：1 / 13

页数：13

共 125 条

[1] Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Liu, Yan ;

Dries, Ruben ;

Bufe, Lauren E. ;

Silkes, Michael ;

Alath, M. D. Maksudul ;

Magee, Dillon M. ;

Jones, Robert ;

Jinushi, Masahisa ;

Kulkarni, Meghana ;

Carretero, Julian ;

Wang, Xiaoen ;

Warner-Hatten, Tiquella ;

Cavanaugh, Jillian D. ;

Osa, Akio ;

Kumanogoh, Atsushi ;

Freeman, Gordon J. ;

Awad, Mark M. ;

Christiani, David C. ;

Bueno, Raphael ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) :1268-1279

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs [J].

Allard, Bertrand ;

Pommey, Sandra ;

Smyth, Mark J. ;

Stagg, John .

CLINICAL CANCER RESEARCH, 2013, 19 (20) :5626-5635

[4]

[Anonymous], 2020, JAMA, DOI [DOI 10.1001/JAMA.2020.2717, DOI 10.1001/JAMA.2014.13943]

[5] In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy [J].

Arlauckas, Sean P. ;

Garris, Christopher S. ;

Kohler, Rainer H. ;

Kitaoka, Maya ;

Cuccarese, Michael F. ;

Yang, Katherine S. ;

Miller, Miles A. ;

Carlson, Jonathan C. ;

Freeman, Gordon J. ;

Anthony, Robert M. ;

Weissleder, Ralph ;

Pittet, Mikael J. .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (389)

[6] Coinhibitory Pathways in Immunotherapy for Cancer [J].

Baumeister, Susanne H. ;

Freeman, Gordon J. ;

Dranoff, Glenn ;

Sharpe, Arlene H. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 34, 2016, 34 :539-573

[7] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].

Benci, Joseph L. ;

Xu, Bihui ;

Qiu, Yu ;

Wu, Tony J. ;

Dada, Hannah ;

Twyman-Saint Victor, Christina ;

Cucolo, Lisa ;

Lee, David S. M. ;

Pauken, Kristen E. ;

Huang, Alexander C. ;

Gangadhar, Tara C. ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Feldman, Michael D. ;

Ishwaran, Hemant ;

Vonderheide, Robert H. ;

Maity, Amit ;

Wherry, E. John ;

Minn, Andy J. .

CELL, 2016, 167 (06) :1540-+

[8] Genomic Approaches to Understanding Response and Resistance to Immunotherapy [J].

Braun, David A. ;

Burke, Kelly P. ;

Van Allen, Eliezer M. .

CLINICAL CANCER RESEARCH, 2016, 22 (23) :5642-5650

[9] Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy [J].

Buckanovich, Ronald J. ;

Facciabene, Andrea ;

Kim, Sarah ;

Benencia, Fabian ;

Sasaroli, Dimitra ;

Balint, Klara ;

Katsaros, Dionysios ;

O'Brien-Jenkins, Anne ;

Gimotty, Phyllis A. ;

Coukos, George .

NATURE MEDICINE, 2008, 14 (01) :28-36

[10] Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab [J].

Chaput, N. ;

Lepage, P. ;

Coutzac, C. ;

Soularue, E. ;

Le Roux, K. ;

Monot, C. ;

Boselli, L. ;

Routier, E. ;

Cassard, L. ;

Collins, M. ;

Vaysse, T. ;

Marthey, L. ;

Eggermont, A. ;

Asvatourian, V. ;

Lanoy, E. ;

Mateus, C. ;

Robert, C. ;

Carbonnel, F. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1368-1379

← 1 2 3 4 5 6 7 8 9 10 →